Prior to Amydis, he has served in leading roles at MedAvante, Johnson & Johnson and Merck, and currently serves on two Scientific Advisory Boards and Data Safety Monitoring Boards. As Senior Vice President for CNS, Pain and Translational Medicine at J&J, Dr. Reines oversaw the development and approval of numerous drugs for the treatment of schizophrenia, Alzheimer’s, pain and migraine headache. Prior to that, Dr. Reines served as Vice President, Clinical Research at Merck with responsibilities for Psychopharmacology, Neuropharmacology, Gastroenterology, and Ophthalmology. While there, he oversaw the conduct of the first large, multicenter trial of a COX-2 inhibitor for prevention of Alzheimer’s disease and led the development of leading brand drugs for nausea and vomiting, migraine, Parkinson’s and glaucoma.